Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, Ko YD, Reinhardt HC, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel KC. Leypoldt LB, et al. Among authors: reinhardt hc. Leukemia. 2022 Mar;36(3):885-888. doi: 10.1038/s41375-021-01431-x. Epub 2021 Nov 3. Leukemia. 2022. PMID: 34732857 Free PMC article. Clinical Trial. No abstract available.
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, Lilienweiss E, Reinhardt HC, Cramer P, Eichhorst B, Hillmen P, O'Brien SM, Pettitt AR, Hallek M. Kreuzer KA, et al. Among authors: reinhardt hc. Leukemia. 2020 Jan;34(1):296-300. doi: 10.1038/s41375-019-0533-6. Epub 2019 Aug 19. Leukemia. 2020. PMID: 31427720 Free PMC article. Clinical Trial. No abstract available.
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
Jachimowicz RD, Klapper W, Glehr G, Müller H, Haverkamp H, Thorns C, Hansmann ML, Möller P, Stein H, Rehberg T, von Tresckow B, Reinhardt HC, Borchmann P, Chan FC, Spang R, Scott DW, Engert A, Steidl C, Altenbuchinger M, Rosenwald A. Jachimowicz RD, et al. Among authors: reinhardt hc. Leukemia. 2021 Dec;35(12):3589-3593. doi: 10.1038/s41375-021-01314-1. Epub 2021 Jun 10. Leukemia. 2021. PMID: 34112956 Free PMC article. No abstract available.
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, Einsele H, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C; Study Alliance Leukemia (SAL). Hanoun M, et al. Among authors: reinhardt hc. J Cancer Res Clin Oncol. 2023 Jul;149(8):4611-4621. doi: 10.1007/s00432-022-04356-9. Epub 2022 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 36167894 Free PMC article. Clinical Trial.
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
Seifert R, Kersting D, Rischpler C, Sandach P, Ferdinandus J, Fendler WP, Rahbar K, Weckesser M, Umutlu L, Hanoun C, Hüttmann A, Reinhardt HC, von Tresckow B, Herrmann K, Dührsen U, Schäfers M. Seifert R, et al. Among authors: reinhardt hc. Leukemia. 2022 Dec;36(12):2845-2852. doi: 10.1038/s41375-022-01713-y. Epub 2022 Oct 14. Leukemia. 2022. PMID: 36241697 Free PMC article. Clinical Trial.
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Huelsemann MF, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, Becker HJ, Theurich S, von Bergwelt-Baildon M, Pallasch CP, Zahedi RP, Kashkar H, Reinhardt HC, Hallek M, Wendtner CM, Frenzel LP. Huelsemann MF, et al. Among authors: reinhardt hc. Leukemia. 2015 Apr;29(4):981-4. doi: 10.1038/leu.2014.320. Epub 2014 Nov 7. Leukemia. 2015. PMID: 25376373 No abstract available.
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
Oubari S, Naser E, Papathanasiou M, Luedike P, Hagenacker T, Thimm A, Rischpler C, Kessler L, Kimmich C, Hegenbart U, Schönland S, Rassaf T, Reinhardt HC, Jöckel KH, Dürig J, Dührsen U, Carpinteiro A. Oubari S, et al. Among authors: reinhardt hc. Eur J Haematol. 2021 Oct;107(4):449-457. doi: 10.1111/ejh.13681. Epub 2021 Jul 9. Eur J Haematol. 2021. PMID: 34185342
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M. Nagler A, et al. Among authors: reinhardt hc. Bone Marrow Transplant. 2022 Jul;57(7):1116-1123. doi: 10.1038/s41409-022-01693-8. Epub 2022 Apr 30. Bone Marrow Transplant. 2022. PMID: 35501565
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M. Nagler A, et al. Among authors: reinhardt hc. Bone Marrow Transplant. 2022 Dec;57(12):1854. doi: 10.1038/s41409-022-01834-z. Bone Marrow Transplant. 2022. PMID: 36207624 No abstract available.
Evolutionary trajectories of small cell lung cancer under therapy.
George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, Jürgens J, Stoelben E, Brockmann M, Grau S, Sebastian M, Stratmann JA, Kern J, Hummel HD, Hegedüs B, Schuler M, Plönes T, Aigner C, Elter T, Toepelt K, Ko YD, Kurz S, Grohé C, Serke M, Höpker K, Hagmeyer L, Doerr F, Hekmath K, Strapatsas J, Kambartel KO, Chakupurakal G, Busch A, Bauernfeind FG, Griesinger F, Luers A, Dirks W, Wiewrodt R, Luecke A, Rodermann E, Diel A, Hagen V, Severin K, Ullrich RT, Reinhardt HC, Quaas A, Bogus M, Courts C, Nürnberg P, Becker K, Achter V, Büttner R, Wolf J, Peifer M, Thomas RK. George J, et al. Among authors: reinhardt hc. Nature. 2024 Mar;627(8005):880-889. doi: 10.1038/s41586-024-07177-7. Epub 2024 Mar 13. Nature. 2024. PMID: 38480884 Free PMC article.
171 results